COVID-19 has left no part of life untouched, including health technology assessment (HTA) and other payer agency activities, and it will likely have a lasting impact on market access.
Experts from Research Partnership analyse the company’s Therapy Watch data to identify how market access policy has impacted the adoption of biosimilars.
The disconnect between payers and pharma companies is just one symptom of pharma’s outdated business model, according to Janssen’s company group chairman EMEA, Kris Sterkens.